Keywords serum cleaved tau protein - mild traumatic brain injury - emergency - diagnostic -
prognostic marker
Introduction
Traumatic brain injury (TBI), also known as intracranial injury , occurs when there is an external blow to the brain, which is commonly caused by
vehicle accidents, bad falls, and violence. Intracranial injuries are associated with
high rates of mortality and morbidity.[1 ] The incidence of TBI in the United States is between 180 and 250 per 100,000 per
year; whereas in Europe, it is estimated to be 235 per 100,000 per year.[2 ]
[3 ] In India, the incidence was 160 per 100,000 per year in an epidemiological study
by the National Institute of Mental Health and Neurosciences (NIMHANS) on neurotrauma.[4 ]
TBIs can be classified on the basis of severity as mild, moderate, and severe.[5 ] TBI has two phases: the primary injury occurring during impact, and the secondary
injury occurring in the hours and days following the initial insult, caused by brain
edema, free radical formation, or the release of inflammatory mediators, which exacerbate
the initial injury by mediating cell damage or death resulting in a poor neurologic
outcome.[6 ]
[7 ] Efforts are aimed to either prevent or reduce the secondary phase of head injury.
In the emergency settings, mainstay of treatment begins with clinical evaluation that
includes Glasgow coma scale (GCS) evaluation, neurologic examination, and the imaging
techniques such as computed tomography (CT) scanning and magnetic resonance imaging
(MRI).[6 ] Till date, no single brain-specific biomarker has been unanimously accepted for
routine clinical use in TBI.[8 ] A biomarker is an indicator of a specific biological or disease state that can be
measured using samples taken from either the affected tissue or peripheral body fluids
and they can be altered enzymatic activity, changes in protein expression, or posttranslational
modification, altered gene expression, protein, or lipid metabolites, or a combination
of these changes.[9 ]
Currently, biochemical markers are playing an important role in other emergency clinical
settings, for example role of troponins in diagnosing and deciding the line of treatment
in patients with chest pain. Thus, more research is required on similar lines to find
any guiding biomarker in TBI cases.
Tau protein is a highly soluble microtubule-associated protein (MAP) associated with
microtubule stabilization in neurons. It is highly expressed in thin, nonmyelinated
axons of cortical interneurons, thus having distinct regional distributions in the
brain, which might be helpful in determining which areas of the brain have been affected
by TBI.[10 ] After release, this protein is proteolytically cleaved at the N- and C-terminals
and diffuses into the cerebrospinal fluid (CSF) and plasma.[11 ] The molecular weight of C-tau in humans after TBI is 30 to 50 kDa. Monoclonal antibodies
that recognize this cleaved form of tau protein used in an enzyme-linked immunosorbent
assay (ELISA) format can be used to quantify serum levels of the cleaved tau protein
(τC ).[12 ]
Besides conventional techniques, no definitive diagnostic marker for therapeutic use
to assess the severity and prognosis of TBI exists till date. Except for research
purposes, no test specifically designed to diagnose TBI is available commercially.
The authors chose to study cleaved tau protein as source of this 30- to 50-kDa protein
are neurons and glia and lack any extracerebral source unlike S100, NSE that also
have extracerebral source. Thus, C-tau is specific to central nervous system (CNS)
tissue and one of the less studied biomarkers in TBI especially the cleaved form.
Therefore, newer tests are required in TBI as early as possible to ensure better patient
survival and lesser long-term neurologic sequelae.
Materials and Methods
This prospective pilot study was conducted on patients presenting at the emergency
department with TBI from January 2014 to July 2015. In this study, patients were included
in this study as per the inclusion and exclusion criteria shown in the following text.
The study was approved by the institutional ethical committee.
Inclusion Criteria
The inclusion criteria included the following: age > 18 years, closed head injury,
no severe coagulopathy that was defined as clinical evidence of excessive bleeding,
platelet counts < 1,00,000, international normalized ratio > 1.4, or partial thromboplastin
time > 50, no clinical indication for future anticoagulation, for example life-threatening
deep vein thrombi, pulmonary embolism, family, or next-of-kin available to provide
written informed consent.
Exclusion Criteria
The exclusion criteria included the following: age < 18 years, presented in emergency
department 12 hours after injury, nonavailability of blood sample, pregnancy, patients
with Alzheimer's disease, athletes, boxers, prolonged cardiac arrest at the scene
of the accident, or high cervical spinal cord injury, and those who had died from
uncontrollable hemorrhage or multiple life-threatening associated injuries.
Sample Size
A total of 40 patients of mild TBI were enrolled in the study from January 2014 to
July 2015, along with 40 healthy volunteers from blood bank who served as the control
group.
Study Protocol
Patients presenting within 12 hours of injury were included in study. Patients' demographic
information was recorded at the time of enrolment. The GCS score was calculated at
the time of admission, third day, and on seventh day during hospitalization. The GCS
was measured on a 3 to 15 point scale with highest score reflecting normal performance.
Time of injury, associated injuries and time of patient arrival at the hospital emergency,
and cranial CT scan findings were recorded. The mechanism of injury was categorized
as falls, assaults, motor vehicle crashes, or any other mode depending on the case.
Clinical outcome was assessed with the Glasgow outcome scale (GOS). Patients were
divided into two groups on basis of GOS: good-outcome group with GOS IV and V and
poor-outcome group with GOS I, II, and III.
Venous blood samples from enrolled patients were collected at time of presentation
into 10-mL serum separator tubes (SSTs). After collection, the samples were allowed
to clot for 2 hours at room temperature or overnight at 4°C and then centrifuged at
13,000 g for 15 minutes. The serum samples were frozen at −70°C (−94°F) and later
assayed for cleaved tau (τC ) protein using ELISA technique. Human cleaved MAP tau (C-MAPT/C-TAU) ELISA kit (BY
CUSABIO-CSB-ECL013481H) available for research purposes was used in this study. A
standard curve by plotting the mean absorbance for each standard on the x-axis against
the concentration on the y-axis was constructed, and a best-fitting curve through
the points on the graph was made and samples serum C-tau values were obtained. Patients'
outcome was assessed at 6-month follow-up using GOS.
Statistical Analysis
Statistical analysis was done using SPSS 20 (IBM Corp. Released 2011. IBM SPSS Statistics
for Windows, Version 20.0. Armonk, New York). Demographic characteristics and clinical
features of the patients were analyzed according to mean ± standard deviation (SD)
and range (minimum-maximum). The normal distributions were analyzed applying the Kolmogorov-Smirnov
test, and mean in two or more groups was then analyzed using Mann-Whitney U test. Furthermore, the Kruskal-Wallis test was then used to compare differences among
groups followed by Tukey's test in case of significant difference. p < 0.05 was considered as statistically significant.
Results
In this study, 456 patients were admitted in the emergency department of neurosurgery,
out of whom 146 patients had head injury. Considering the selection criteria, 40 patients
of mild TBI and 40 healthy volunteers from blood bank as controls were finally included
in the study ([Table 1 ]).
Table 1
Demographic characteristics and serum C-tau protein levels
Characteristics
mild TBI cases
Control
C- tau protein level in mild TBI (mean ± SD) pg/mL
p Value
Male
31 (77.5%)
33
46.21 ± 23.65
p
[a ] = 0.544
Female
9 (22.5%)
7
39.78 ± 21.61
Mean age in years (range)
39.45 ± 15.60,(18–78)
37.35 ± 12.93,(18–68)
Mechanism of injury
RTA
25
–
50.48 ± 25.86
p
[b ] = 0.132
Fall from height
3
–
52.12 ± 13.18
Assault
9
–
29.41 ± 11.03
Fall of heavy object on head
2
–
39.00 ± 6.42
Sports injury
1
–
–
GCS score
At the time of admission (mean)
14.025
–
p
[b ] < 0.001
13
15
–
65.15 ± 22.41
14
6
–
43.87 ± 9.67
15
16
–
26.15 ± 9.13
Abbreviations: GCS, Glasgow coma scale; RTA, road traffic accident; SD, standard deviation;
TBI, traumatic brain injury.
a Independent-samples Mann-Whitney U test.
b Independent-samples Kruskal-Wallis test.
In the study group, the mean age was 39.45 ± 15.60 years, minimum age was 18 years,
and maximum age was 78 years. The mean age in the control group was 37.35 ± 12.93
years, minimum age was 18 years, and maximum age was 68 years. In this study, the
mild TBI group, comprised 31 males (77.5%) and 9 females (22.5%) (n = 40) and the male-to-female ratio was 3.4:1. The most common mode of injury was
road traffic accident (RTA) followed by assault, fall from height, fall of object
on head, and sports injury. Maximum number of patients had GCS 15, followed by GCS
13 and 14. All patients who presented with history of TBI underwent routine investigations
along with NCCT (noncontrast CT) head scanning. CT findings were found negative in
35% patients (n = 14), whereas majority of (65%) patients had positive findings viz. contusion/intraparenchymal
hematomas in 35% (n = 14), skull bone fracture (linear and depressed) in 17.5% (n = 7), subarachnoid hemorrhage (SAH) in 5% (n = 2), subdural hemorrhage (SDH) in 5% (n = 2), and extradural hemorrhage (EDH) in 2.5% (n = 1). Approximately 90% of patients (n = 36) in the mild TBI group were managed conservatively. However, 10% patients (n = 4) in mild TBI underwent surgical intervention, depending on the type of injury.
Serum C-tau Protein
The mean serum tau protein level in the study group was 44.76 ± 23.10 pg/mL (range:
12.32–96.44, 95% confidence interval [CI]: 37.37–52.15). The mean serum tau protein
level in the control group was 33.82 ± 13.65 pg/mL, (range: 2.48–66.54, 95% CI: 29.46–38.19).
Compared with controls, this difference in mean serum C-tau protein was not statistically
significant (p = 0.091). The mean serum cleaved tau protein level in males was 46.21 ± 23.65 pg/mL
(range: 12.32–96.44) and in females was 39.78 ± 21.61 pg/mL (range: 12.34 ± 85.66).
This difference in serum tau levels with reference to sex was, however, not significant
statistically (p = 0.54).
The mean serum C-tau level was 65.15 ± 22.41, 43.87 ± 9.67, 26.15 ± 9.13 pg/mL in
patients with GCS 13, 14, and 15, respectively, at zeroth day. Serum C-tau levels
were significantly lower in patients with GCS 15 compared with in patients with GCS
14 (p = 0.011). Also, C-tau was significantly lower in GCS 15 as compared with GCS 13 (p = 0.000).
Mode of Injury and Serum C-tau Protein Levels
The mean C-tau levels in RTA cases 50.48 ± 25.86 pg/mL, assault 29.41 ± 11.03 pg/mL,
fall from height 52.12 ± 13.18 pg/mL, fall of object on head 39.00 ± 6.42 pg/mL (p = 0.132).
Computed Tomography Findings and Serum C-tau Protein Levels
CT scans demonstrated intracranial injury in 26 patients with mild TBI. The difference
between the serum tau protein values of patients with normal CT scans (26.96 ± 8.91
pg/mL) and those with evidence of injury on CT (54.36 ± 22.75 pg/mL) was statistically
significant (p < 0.001).
Glasgow Outcome Score and Serum C-tau Levels
With reference to the outcome of the patients at discharge, serum cleaved tau protein
levels within 12 hours of injury were correlated with good- and poor-outcome groups
in mild TBI ([Table 2 ]). In this study, 36 patients had good outcome and 4 had poor outcome.
Table 2
CT findings, GOS at discharge and serum C-tau protein levels
Results
Mild TBI cases (%)
Serum C-tau levels(Mean ± SD) pg/mL, range (max-min)
p Value
CT findings
Negative CT scan
14 (35%)
26.96 ± 8.91
p
[a ] < 0.001
Skull bone fracture (linear and depressed)
7 (17.5%)
41.57 ± 5.87
Contusion/intraparenchymal hematomas
14(35%)
66.45 ± 19.31
SDH
2 (5%)
62.63 ± 36.87
SAH
2 (5%)
26.04 ± 4.94
EDH
1 (2.5%)
–
GOS at discharge
Good outcome (GOS IV, V)
36 (90%)
40.77 ± 19.63, 12.32–88.71
p
[b ] = 0.004
Poor outcome (GOS I ,II, III)
4 (10%)
80.66 ± 23.10, 46.55–96.44
Abbreviations: CT, computed tomography; EDH, extradural hemorrhage; GOS, Glasgow outcome
score; SAH, subarachnoid hemorrhage; SD, standard deviation; SDH, subdural hemorrhage;
TBI, traumatic brain injury.
a Kruskal-Wallis test for independent samples.
b Mann-Whitney U test.
Serum cleaved tau protein levels in the good-outcome group were significantly lower,
that is, 40.77 ± 19.63 pg/mL (mean ± SD) (range: 12.32–88.71, 95% CI: 34.13–47.42)
compared with the poor-outcome group 80.66 ± 23.10 pg/mL (mean ± SD) (range 46.55–96.44,
95% CI: 43.88–117.43, p = 0.004).
Glasgow Outcome Score at 6 Months Follow-Up
After 6 months, 32 patients had good outcome and 5 patients were lost to follow-up.
Discussion
This study was a sincere attempt to identify the role of cleaved form of an axonal
protein—“tau”—in mild TBI. Various correlations of C-tau with different variables
were investigated in this study. The patients were of various age groups: most patients
belonged to 28- to 37-year age group (32.5%), followed by 18- to 27-year age group
(22.5%). In mild TBI group (n = 40), the mean age was 39.45 ± 15.60 years (18–78 years). Bulut et al included 60
cases of mild TBI with the mean age of cases being 32.5 years (15–66 years).[1 ] Wuthisuthimethawee et al reported the mean age in their study as 34.9 ± 15.6 years
(range: 15–74), focusing on minor head trauma.[13 ] In another study by Zemlan et al (1999), mean age was 32.4 ± 14.1 years.[12 ] These are studies from various geographic regions of the world, and all of them
reflect that TBI is more often seen in the most productive age group that comprise
a larger part of population and directly have an impact on economy of countries, as
they are more involved and exposed to the daily outdoor activities. This demands more
sincere efforts to be directed in finding out research molecules in TBI to reduce
the mortality and morbidity. In this study, maximum patients were males (M:F ratio:
3.4:1). A review by Bruns and Hauser on epidemiology of TBI mentioned that the demographic
groups at high risk for TBI include males and individuals living in regions characterized
by socioeconomic deprivation.[2 ]
There was no statistically significant difference in males and females with reference
to serum cleaved tau levels (p = 0.54) in this study. The authors found no correlation of serum C-tau levels with
sex in mild TBI cases in this study. Similar were the findings in other studies. In
a study concerning minor head trauma, no statistically significant difference in serum
tau levels in males (16.62 pg/mL [2.12–215.97 pg/mL]) and females (17.60 pg/mL [3.42–714.47
pg/ mL]) was witnessed by Kavalci et al.[14 ] A study concerning pediatric patients with minor head trauma conducted by Guzel
et al reported serum tau protein levels to be 84.91 ± 69.30 pg/mL (5.14–367.29) and
73.0 ± 60.06 pg/mL (5.71–230.43) in male and female patients, respectively, which
was insignificant statistically (p = 0.197).[15 ] Thus, various studies reported that no significant difference exist in serum tau
levels with reference to males and females in TBI. This shows that serum C-tau level
is a sex-independent variable in head trauma.
In this study, the most common mode of injury in cases of mild TBI was RTA, followed
by assault, fall from height, fall of object on head, and sports injury. In mild head
injury case, mode of injury showed no significant difference in levels of serum C-tau
in this study (p = 0.132) ([Fig. 1 ]).
Fig. 1 Box plot showing comparison of serum C-tau protein levels and mode of injury in mild
TBI (p = 0.132). FFH, fall from height; RTA, road traffic accident.
In an epidemiologic study by NIMHANS, India, the most common cause of TBI was RTI
(62%), followed by falls (22%), assaults (10%), and fall of objects (8%).[4 ] Odero et al conducted a review of RTIs and found that in developing nations, pedestrians,
motorcyclists and bicyclists together were at high risk of sustaining head injuries.[16 ] This fits well to Indian context also but not in Western countries where motor vehicle
occupants are at a greater risk compared with motorcyclists and bicyclists.
The authors found that mean serum C-tau levels (44.76 ± 23.10 pg/mL) were higher than
those in the controls (33.82 ± 13.65 pg/mL) in this study, but this difference was,
however, not statistically significant ([Fig. 2 ]). This supports that in mild TBI, serum C-tau protein does not truly reflect the
internal pathological changes in brain matter posttrauma, and for tau proteins to
be released into serum from CSF through blood-brain barrier, trauma should be greater
in intensity, volume, and with axonal involvement. Not many studies are available
on C-tau levels in mild TBI ([Table 3 ]).
Table 3
Studies conducted on tau protein till date focusing mild TBI
Year
Author
Study group
TBI
Control
Sample
GCS
Test
Results
Other findings
Mild head injury
2006
Bulut et al[1 ]
60 adults
Mild TBI
20
Serum
Mean scale (GCS) score was 14 ± 0.6
Specific sandwich ELISA (Innotest hTAU-Ag, Innogenetics, Gent, Belgium)
S. tau levels of patients (188 ± 210 pg/mL), compared with those of controls (86 ± 48
pg/mL), not statistically significant (p = 0.445)
S. tau levels of high-risk patients (307 ± 246 pg/mL) were significantly higher compared
with the low-risk patients (77 ± 61 pg/mL) (p =.001).
2007
Kavalci et al[14 ]
33 patients (group 2)
Minor head trauma
55 patients (group 1)
Serum
–
Not mentioned
Group 1 (n = 55) median serum tau protein level was 16.29 pg/mL (2.12–215.97 pg/mL) and group
2 (n = 33) median serum tau protein level was 18.39 pg/mL (2.19–714.47 pg/mL)
Statistical analysis revealed no significant difference between the 2 groups for tau
protein values, sex, age, mechanism of trauma, and GCS score.
2008
Ma et al[17 ]
50 adults
Mild TBI
–
Serum
–
ELISA
τC is a poor predictor of PCS after mild TBI regardless of CT scan result of the head
15 patients had detectable levels of τC , 10 patients had abnormal findings on initial CT of the head and 22 patients had
PCS.
2010
Guzel et al[15 ]
1–14 y-old group 1–30 patients with normal CCT findings, group 2–30 patients with
intracranial lesions
Mild TBI
1–14 y-old group 3–28 control
Serum
–
Human tau immunoassay kit (BioSource International, Camarillo, California, United
States) with sandwich ELISA
Mean S. tau levels: group 1 96.06 ± 70.36 pg/mL, group 2 112.04 ± 52.66 pg/mL, no
statistically significant difference between the groups (p = 0.160).
Serum tau protein increased after minor head trauma, but concentrations are not associated
with ICI. GCS score and pathologic condition in CCT were only influential variables
on tau protein levels.
2013
Wuthisuthimethawee et al[13 ]
44 cases
Mild TBI
12 healthy volunteers (control group)
Serum
Median GCS was 15
Human Tau phosphoSerine 396 ELISA (hTau pS396) kit (BioSource International, Inc.,
Camarillo, California, United States).
Positive at a cutoff point of 0.1 pg/mL. Serum τC not detected in either control group
or the patients with mild TBI. Serum τC level considered positive if > 0.1 pg/mL.
No correlation of serum τC with mild TBI was observed; proved to be an unreliable marker in early detection
of and decision making in emergency.
Animal studies on tau proteins
2001
Irazuzta et al[18 ]
Rats
Experimental bacterial meningitis (using type III GBS)
Brain tissue CSF, serum
C-tau sandwich ELISA quantification of serum, CSF and heat-stable tau proteins.
Whole-brain τC were significantly elevated in high-dose GBS inoculated animals compared with controls.
τC appears in S.; reflects the extent of neurologic damage. Neurobehavioral performance
altered after bacterial meningitis and could be correlated with histologic and biochemical
markers of neurologic sequelae.
Abbreviations: CCT, contrast-enhanced computed tomography; CSF, cerebrospinal fluid;
C-tau/τC , cleaved tau protein; ELISA, enzyme-linked immunosorbent assay; GBS, group B Streptococcus ; GCS, Glasgow coma scale; ICI, intracranial injury; PCS, postconcussion syndrome;
TBI, traumatic brain injury.
Fig. 2 Comparison of serum C-tau levels in mild TBI and controls (applying Mann-Whitney
U test).
Mareka et al in 2008 also could not find any significant role of C-tau in serum in
mild TBI. They reported that mean serum C-tau concentration was 5.02 ng/mL (SD 2.98
ng/mL). Their lowest detection limit of serum C-tau ELISA was 1.5 ng/mL. They reported
that serum C-tau was not detected more frequently in all patients (p = 0.115) or in the subgroup with negative head CT scans (p = 0.253).[17 ] No serum cleaved tau protein could be detected by Wuthisuthimethawee et al in 2013
in either the healthy control group or the patients with mild TBI.[13 ] They concluded that there was no correlation of serum cleaved tau level in mild
TBI, thus making it an unreliable marker in early detection and decision making in
mild TBI injury patients at the emergency department. Thus, an increase in serum C-tau
levels occurring after mild head trauma does not signify it to the tune of diagnostic
significance. It is important to mention that C-tau protein differs slightly from
tau protein. After head injury, proteolytic cleavage of tau protein weighing 48 to
68 kDa results in a truncated tau protein weighing 30 to 50 kDa and is comparatively
shorter as it lacks the N- and C-terminal domains.[19 ] Also, different investigators have used different measurement methods; thus, these
comparisons should be viewed with caution. Other studies on mild TBI are available,
which detected tau protein in serum. A study on serum tau protein by Bulut et al in
mild TBI measured that tau levels in serum in cases (188 ± 210 pg/mL) was not significantly
higher than those in the controls (86 ± 48 pg/mL). However, in their study serum tau
protein in high-risk patients (307 ± 246 pg/mL) was significantly higher than that
in low-risk patients (77 ± 61 pg/mL) and controls (p =.002).
The mean serum C-tau level in patients with GCS 13, 14, and 15 was 65.15 ± 22.41,
43.87 ± 9.67, 26.15 ± 9.13 pg/mL, respectively, at zeroth day ([Fig. 3 ]). Serum C-tau levels were significantly lower in patients with GCS 15 compared with
patients with GCS 14 (p = 0.011). This shows that level of serum C-tau varies with the change in GCS. In
this study, patients with lower GCS had significantly higher level of serum C-tau
protein, which was associated with poor outcome. This difference in levels may be
studied in further detail with many large studies focused on timely C-tau measurements
while correlating with GCS scores. Correlating the serum C-tau levels and the GCS
at which it is significant may help the authors guide further in qualitatively analyzing
the significant serum tau levels and may shed some light on its role in projecting
TBI prognosis. Liliang et al found in their study that the GCS score and the serum
C-tau protein level were significantly associated with clinical outcome. To the contrary,
Guzel et al found no statistically significant difference in serum tau protein levels
according to GCS scores.
Fig. 3 Box plot showing serum C-tau protein levels in patients with mild TBI (Glasgow coma
scale [GCS] 13, 14, 15).
In mild TBI, mean serum C-tau level in CT-positive group was significantly higher
than that in CT-negative group (p < 0.001) ([Fig. 4 ]). These results signify that this increase in serum C-tau level may be used to discriminate
between patients with and without intracranial lesions, irrespective of the severity
of injury. This finding may prove to be of highly diagnostic importance in TBI in
which findings may be absent in CT, but intracranial injury is present, and may differentiate
between presence and absence of head injury without considering the severity. This
may be of immense help in primary centers in identifying patients who will definitively
require tertiary health care using a safe and simple blood test and at a comparatively
lesser cost. Besides, it may have an important role in medicolegal cases in identifying
presence or absence of head injury. Similar results were found in a pilot study by
Shaw et al on adult patients with closed head injury, where the initial C-tau level
of > 0 significantly correlated with a greater chance of intracranial injury on the
initial CT of the head, but their study had a limitation in that it did not mentioned
the actual serum C-tau levels. Contrary to these results, Kavalci et al in 2007 reported
that serum tau levels increased but not significantly in patients with minor head
trauma who had intracranial lesions in cranial CT (18.39 pg/mL [2.19–714.47 pg/mL])
compared with patients with negative CT findings (16.29 pg/mL [2.12–215.97 pg/mL]).[14 ] Bulut et al found no significant difference between the serum tau protein values
of patients with normal cranial CT scans (150 ± 163 pg/mL) and of those with established
disease (201 ± 223 pg/mL) (p = 0.473) in mild head injury. Another similar study by Guzel et al focusing on pediatric
patients with minor head trauma projected that the difference in serum tau protein
level in normal CT group (96.06 ± 70.36 pg/mL) as compared with positive CT group
(112.04 ± 52.66 pg/mL) was not statistically significant.[15 ] However, these comparisons should be viewed with caution as these studies were focused
on serum tau levels.
Fig. 4 Box plot showing comparison between serum C-tau levels of patients and computed tomography
(CT) findings in mild TBI (p < 0.001). EDH, extradural hemorrhage; ICH, intracerebral hemorrhage; SAH, subarachnoid
hemorrhage; SDH, subdural hemorrhage.
In mild TBI group, serum C-tau levels in the good-outcome group were significantly
lower, that is, 40.77 ± 19.63 pg/mL, than with the poor-outcome group, that is, 80.66 ± 23.10
pg/mL (p = 0.004). Thus, significantly higher serum C-tau levels in patients with poor outcome
indicate utility of this protein in predicting the disease prognosis. Similar promising
results were also found in other studies; for example, in a study by Shaw et al, results
showed that those with a serum C-tau level of > 0 were more likely to have a poor
outcome, (odds ratio: 8.17, 95% CI: 1.42–47).[11 ] The sensitivity and specificity of serum C-tau for predicting outcome in their study
was 64% (95% CI: 37–82%) and 82% (95% CI: 65–94%), respectively.
Taking into consideration the biochemical and pathophysiological changes following
trauma, efforts are continuing to find diagnostic biomolecules that can reflect these
in vivo pathologic changes occurring after TBI. The availability of such biomarkers
may supplement currently available methods and may help quantify the extent of damage,
especially in patients with closed head injury without loss of time, which is one
of the most neglected factors in developing countries. Besides, availability of CT
scans, high costs, and radiation exposure are some other factors that potentiate the
need to search for other tools of early identification of TBI.
The authors observed that patients with high serum C-tau levels were found to be significantly
associated with poor outcome. In mild TBI group, serum C-tau levels in the good outcome
group were significantly lower than those in the poor-outcome group (p = 0.004). Similar promising results were also found in other studies. The degree
of brain injury depends on the magnitude of injury, secondary insults, and patient's
genetic and molecular response.[20 ]
Diagnosing TBI using clinical and radiologic parameters forms the cornerstone of treatment
in the current scenario, but all have their limitations. For example, clinically,
GCS cannot detect subtle neurologic signs such as latent paresis. Radiological imaging
techniques such as CT scan cannot detect diffuse axonal injury, which otherwise is
an important finding. Limitations of one parameter may be overcome by other parameter;
thus, using combination of these parameters may increase the diagnostic and prognostic
accuracy.
The sample size in this study was too small to reach a definitive conclusion. Furthermore,
no measurement of CSF C-tau was done as CSF sampling was an invasive procedure. This
study lacked in temporal serum and CSF C-tau measurements and its correlation that
would be very beneficial in understanding the disease pathogenesis.
Conclusion
In this study, serum C-tau levels in patients with mild TBI were comparatively higher
than those in the controls. Patients with lower GCS had significantly higher level
of serum C-tau protein and poor outcome (GOS score), thus indicating role of tau protein
in predicting the disease prognosis. However, reaching a definitive conclusion will
be too early and beyond the scope of this study. Thus, more studies are required in
identifying its role as a diagnostic and prognostic marker in mild TBI.
